CorMedix Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CORMEDIX INC. | ||
| March 25, 2025 | By: | /s/ Joseph Todisco |
|---|---|---|
| Joseph Todisco | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| March 25, 2025 | By: | /s/ Matthew David |
| Matthew David | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Joseph Todisco | Chief Executive Officer and Director | March 25, 2025 |
| Joseph Todisco | (Principal Executive Officer) | |
| /s/ Matthew David | Executive Vice President and Chief Financial Officer | March 25, 2025 |
| Matthew David | (Principal Financial and Accounting Officer) | |
| /s/ Myron Kaplan | Director and Chairman of the Board | March 25, 2025 |
| Myron Kaplan | ||
| /s/ Janet Dillione | Director | March 25, 2025 |
| Janet Dillione | ||
| /s/ Gregory Duncan | Director | March 25, 2025 |
| Gregory Duncan | ||
| /s/ Alan Dunton | Director | March 25, 2025 |
| Alan Dunton | ||
| /s/ Steven Lefkowitz | Director | March 25, 2025 |
| Steven Lefkowitz | ||
| /s/ Robert Stewart | Director | March 25, 2025 |
| Robert Stewart | ||
FINANCIAL STATEMENTS
Financial Statements Index
| Report of Independent Registered Public Accounting Firm (PCAOB ID # 688) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) Years Ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity Years Ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.